Pyxis Oncology (PYXS) Net Cash Flow Growth (1y) (2021 - 2025)
Pyxis Oncology (PYXS) Net Cash Flow Growth (1y) (2021 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,342.66 Bn | 67,342.38 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,887.92 Bn | 1,887.86 Bn | - | - |
| 3 | BeOne Medicines | 471.75 Bn | 466.96 Bn | 1.35 Bn | 301.06% |
| 4 | Vertex Pharmaceuticals | 122.57 Bn | 115.32 Bn | 2.59 Bn | 453.08% |
| 5 | Regeneron Pharmaceuticals | 69.18 Bn | 60.43 Bn | 3.31 Bn | -125.22% |
| 6 | Belite Bio | 61.55 Bn | 61.55 Bn | - | - |
| 7 | Argenx Se | 56.68 Bn | 51.50 Bn | 1.41 Bn | - |
| 8 | Revolution Medicines | 37.83 Bn | 37.83 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 36.81 Bn | 33.80 Bn | 959.66 Mn | 53.46% |
| 10 | Pyxis Oncology | 167.17 Mn | 100.31 Mn | 8.65 Mn | -12.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -12.32% |
| Sep 30, 2025 | 86.07% |
| Jun 30, 2025 | 32.28% |
| Mar 31, 2025 | -136.68% |
| Dec 31, 2024 | 246.84% |
| Sep 30, 2024 | -16.41% |
| Jun 30, 2024 | 91.31% |
| Mar 31, 2024 | 114.50% |
| Dec 31, 2023 | 73.75% |
| Sep 30, 2023 | 54.94% |
| Jun 30, 2023 | -39.62% |
| Mar 31, 2023 | -356.56% |
| Dec 31, 2022 | -113.48% |
| Sep 30, 2022 | -175.87% |
| Jun 30, 2022 | -1,417.86% |
| Mar 31, 2022 | -120.85% |
| Dec 31, 2021 | 4,608.24% |